News | May 14, 2021
Gap between two doses of Covishield extended; No extension for Covaxin
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
Subscribe To Our Newsletter & Stay Updated
